Literature DB >> 18206661

Roles of nitric oxide in inflammatory downregulation of human cytochromes P450.

Alison E Aitken1, Choon-Myung Lee, Edward T Morgan.   

Abstract

The purpose of this study was to determine the role of nitric oxide (NO) in the downregulation of human cytochrome P450 (CYP) enzymes and mRNAs by an inflammatory stimulus in cultured human hepatocytes. We focused on CYP2B6 because previous studies showed that rat CYP2B proteins undergo an NO-dependent degradation in response to inflammatory stimuli. To ensure high-level expression of CYP2B6, the inducer phenytoin was present at all times. Stimulation of cells with a mixture of tumor necrosis factor-alpha, interleukin-1, and interferon-gamma (ILmix) downregulated CYP2B6 mRNA and protein to 9 and 19% of control levels. The NO donor NOC-18 downregulated CYP2B6 protein to 30% of control, with only a small effect on CYP2B6 mRNA. Nitric oxide synthase inhibitors attenuated the downregulation of CYP2B6 protein but not mRNA by ILmix. These findings demonstrate that the posttranscriptional NO-dependent downregulation of CYP2B enzymes, observed previously in rat hepatocytes, is conserved in human CYP2B6. This mechanism is specific for CYP2B6 among the enzymes tested. No evidence was found for regulation of CYP2E1 mRNA or protein by NO. NOC-18 treatment downregulated CYP3A4 mRNA to 50% of control. However, NOS inhibitors failed to block the effects of ILmix on CYP3A4 expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18206661      PMCID: PMC2346593          DOI: 10.1016/j.freeradbiomed.2007.12.010

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  48 in total

1.  Inhibition of nitric oxide synthesis improves detoxication in inflammatory liver dysfunction in vivo.

Authors:  A Veihelmann; T Brill; M Blobner; I Scheller; B Mayer; M Prölls; S Himpel; J Stadler
Journal:  Am J Physiol       Date:  1997-08

2.  Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6.

Authors:  Oksana Kourylko; Caroline Fradette; Mathieu Arcand; Patrick du Souich
Journal:  Drug Metab Dispos       Date:  2005-10-04       Impact factor: 3.922

Review 3.  The 2006 Bernard B. Brodie Award Lecture. Cyp2e1.

Authors:  Frank J Gonzalez
Journal:  Drug Metab Dispos       Date:  2006-10-04       Impact factor: 3.922

Review 4.  Cytochrome P450 ubiquitination: branding for the proteolytic slaughter?

Authors:  Maria Almira Correia; Sheila Sadeghi; Eduardo Mundo-Paredes
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

5.  Liver disease selectively modulates cytochrome P450--mediated metabolism.

Authors:  Reginald F Frye; Nathalie K Zgheib; Gary R Matzke; Diego Chaves-Gnecco; Mordechai Rabinovitz; Obaid S Shaikh; Robert A Branch
Journal:  Clin Pharmacol Ther       Date:  2006-09       Impact factor: 6.875

Review 6.  Regulation of drug-metabolizing enzymes and transporters in inflammation.

Authors:  Alison E Aitken; Terrilyn A Richardson; Edward T Morgan
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

Review 7.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Authors:  Daniel W Nebert; Timothy P Dalton
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

8.  Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins.

Authors:  Choon-Myung Lee; Bong-Yoon Kim; Lian Li; Edward T Morgan
Journal:  J Biol Chem       Date:  2007-11-09       Impact factor: 5.157

9.  Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene.

Authors:  M B Sewer; T B Barclay; E T Morgan
Journal:  Mol Pharmacol       Date:  1998-08       Impact factor: 4.436

Review 10.  Cytochrome P450 pharmacogenetics and cancer.

Authors:  C Rodriguez-Antona; M Ingelman-Sundberg
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  20 in total

1.  Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.

Authors:  Leslie Tompkins; Caitlin Lynch; Sam Haidar; James Polli; Hongbing Wang
Journal:  Pharm Res       Date:  2010-05-26       Impact factor: 4.200

2.  Nitric Oxide Mediated Degradation of CYP2A6 via the Ubiquitin-Proteasome Pathway in Human Hepatoma Cells.

Authors:  John Cerrone; Choon-Myung Lee; Tian Mi; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2020-04-29       Impact factor: 3.922

Review 3.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

Review 4.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

5.  Using a Multi-Stage hESC Model to Characterize BDE-47 Toxicity during Neurogenesis.

Authors:  Hao Chen; Helia Seifikar; Nicholas Larocque; Yvonne Kim; Ibrahim Khatib; Charles J Fernandez; Nicomedes Abello; Joshua F Robinson
Journal:  Toxicol Sci       Date:  2019-06-07       Impact factor: 4.849

6.  Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system.

Authors:  Choon-Myung Lee; Shweta Tripathi; Edward T Morgan
Journal:  Free Radic Biol Med       Date:  2017-04-17       Impact factor: 7.376

7.  M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.

Authors:  Ratanesh Kumar Seth; Suvarthi Das; Sahar Pourhoseini; Diptadip Dattaroy; Stephen Igwe; Julie Basu Ray; Daping Fan; Gregory A Michelotti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

8.  Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease.

Authors:  Edward T Morgan; Cene Skubic; Choon-Myung Lee; Kaja Blagotinšek Cokan; Damjana Rozman
Journal:  Drug Metab Rev       Date:  2020-09-08       Impact factor: 4.518

9.  Nitric oxide stimulates cellular degradation of human CYP51A1, the highly conserved lanosterol 14α-demethylase.

Authors:  Ji Won Park; Aria Byrd; Choon-Myung Lee; Edward T Morgan
Journal:  Biochem J       Date:  2017-09-14       Impact factor: 3.857

10.  Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures.

Authors:  Choon-Myung Lee; Jan Pohl; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.